← Leaderboards
Kohta Saito
Weill Medical Coll Of Cornell Univ
$1,093,093
Attributed
$1,326,155
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $254.3K · FY2019–25$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,326,155 · 2
By mechanism
K08$860,030 · 1
R21$466,125 · 1
Top collaborators
- Christopher David Brown2 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Christopher David Brown$1,207,363
- Sabine Ehrt$39,683,358
- Sarah M. Schrader$194,486
- Lydia Bourouiba$1,927,609
- Kathleen F Walsh$586,440
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsResponseGrowthNutrientPredispositionResistanceFutureGenus MycobacteriumMycobacterium TuberculosisMycolic AcidFoundationsPhenotypeEnzymesPublishingFaceBiologyCell WallGenetic TranscriptionHeterogeneityIn VitroCommunicable DiseasesDesignExposure ToStarvation
Grant awards (7)
Interrogating complex mycobacterial population structures using single-cell RNA sequencing$211,875
R21 · FY2025 · AI · contact PI
Interrogating complex mycobacterial population structures using single-cell RNA sequencing$254,250
R21 · FY2024 · AI · contact PI
Identifying the Molecular Target of Two Novel Compounds Active Against Non-replicating Mycobacterium tuberculosis and Delineating the Role of the Putative Target, InhA, in Non-replicating States$172,006
K08 · FY2023 · AI · contact PI
Identifying the Molecular Target of Two Novel Compounds Active Against Non-replicating Mycobacterium tuberculosis and Delineating the Role of the Putative Target, InhA, in Non-replicating States$172,006
K08 · FY2022 · AI · contact PI
Identifying the Molecular Target of Two Novel Compounds Active Against Non-replicating Mycobacterium tuberculosis and Delineating the Role of the Putative Target, InhA, in Non-replicating States$172,006
K08 · FY2021 · AI · contact PI
Identifying the Molecular Target of Two Novel Compounds Active Against Non-replicating Mycobacterium tuberculosis and Delineating the Role of the Putative Target, InhA, in Non-replicating States$172,006
K08 · FY2020 · AI · contact PI
Identifying the Molecular Target of Two Novel Compounds Active Against Non-replicating Mycobacterium tuberculosis and Delineating the Role of the Putative Target, InhA, in Non-replicating States$172,006
K08 · FY2019 · AI · contact PI